This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Measure of benefit:
The summary benefit measure was the change in the MRAOS, which was derived directly from the RCT.
Cost data:
The economic evaluation included a wide range of services provided in the primary and secondary care settings, education sector, and other community services. A breakdown of items was reported. The resource use was based on data gathered over the study period using a specific case form. All hospital costs incurred by the National Health Service (NHS) were estimated using NHS reference costs. Those incurred in the private sector were derived from direct personal communications with each facility. The unit costs of community health and social services were derived from prices published by the Personal Social Services Research Unit. The costs of schooling came from various official sources. Medication costs were from the British National Formulary. All costs were in UK pounds sterling (£) for the fiscal year 2003 to 2004. Costs in the second year were discounted at 3.5% per annum. Statistical analyses of costs were carried out to consider the potential impact of baseline factors.
Analysis of uncertainty:
The issue of uncertainty was investigated by means of cost-effectiveness acceptability curves based on re-sampling from the costs and effectiveness data (bootstrapping). The authors stated that three one-way sensitivity analyses were carried out to consider the issue of missing data for hospital costs. Full results of the ssensitivity analyses are contained in the data supplement to the online version of the paper.
Results
At two-year follow-up, the MRAOS score was 8.3 for the in-patient group, 8.4 for the specialist out-patient group and 8.3 for the general out-patient group (p=0.838). The bootstrapped means were 8.26 for in-patients, 8.35 for specialist out-patients, and 8.26 for general out-patients.
The mean total two-year costs were £34,531 ± 52,439 in the in-patient group, £26,738 ± 46,809 in the specialist outpatient group, and £40,794 ± 63,652 in the general out-patient group. The differences between groups did not reach statistical significance.
The bootstrapped estimates showed that the specialist out-patient treatment was more effective and less expensive than its comparators, which means it was dominant. The cost-effectiveness acceptability curve indicated that, if the decisionmaker's willingness to pay was zero for a unit of increase in MRAOS score, there was a 78% chance of specialist outpatient services being the most cost-effective strategy, 16% for in-patient services, and 6% for general out-patient services.
Increasing the levels of willingness to pay decreased the probability of specialist out-patient treatment being the most cost-effective, but it remained the preferred strategy in all circumstances. The authors stated that their findings were robust to changes in assumptions about missing data.
